Gennao Bio Announces Abstract Accepted for Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

On September 30, 2021 Gennao Bio, a privately-held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, reported that an abstract reporting preclinical results for its proprietary, non-viral gene monoclonal antibody (GMAB) nucleic acid delivery system has been selected for a poster presentation at the 2021 AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), hosted by the American Association for Cancer Research (AACR) (Free AACR Whitepaper), the National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC) (Press release, Gennao Bio, SEP 30, 2021, View Source [SID1234590598]). The conference will be held virtually from October 7, 2021 to October 10, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Gennao’s GMAB technology platform utilizes a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of multiple types of nucleic acids including messenger ribonucleic aid (RNA), synthetic RNA, RNA interference, deoxyribonucleic acid, antisense oligonucleotides and gene editing molecules. Gennao Bio is developing this delivery system with an initial focus on oncology and monogenic skeletal muscle diseases.

The details of the presentation are as follows:

Title: Systemic targeting of medulloblastoma using a cell-penetrating, nucleic acid binding, monoclonal antibody.
Poster Number: P135
Authors: Elias Quijano, Min Soo Kwang, Bruce C. Turner, Stephen Squinto, Ranjit Bindra, W. Mark Saltzman and Peter M. Glazer.

The full abstract and poster presentation can be accessed on the AACR (Free AACR Whitepaper)-NCI-EORTC annual meeting website beginning October 7, 2021 at 9:00 a.m. ET.